Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Ending “Buy-And-Bill” in Oncology: The Question is How, Not If

This article was originally published in RPM Report

Executive Summary

The public policy debate over affordability of cancer care is approaching consensus on the need to end the “buy-and-bill” model for chemotherapy. How, and how fast, are the key remaining questions. For biopharma manufacturers, there are good reasons to embrace the change.

You may also be interested in...

Who’s Afraid Of Payment Reform? CMS Cardiac Bundle Shows How Changes Can Be Positive For Rx

Medicare’s proposed demonstration project to change payments in Medicare Part B aside, when it comes to ideas for payment and delivery reform, prescription drugs should do pretty well. CMS’ new proposal to bundle cardiac payments is a timely case in point.

J.P. Morgan Notebook, Jan. 13: Drug Costs, Gilead, Valeant, Allergan/Actavis, Bristol

Welcome to “The Pink Sheet” DAILY’s round-up of news and notes from the 2015 J.P. Morgan Healthcare Conference in San Francisco. Pricing talk dominates day two, and companies weigh in on the fallout from failed M&A.

Cutting Cost in Oncology: MD Anderson Tries Episode-Based Payments

At the Institute of Medicine’s National Cancer Policy Forum workshop, MD Anderson Cancer Center gave an update on its pilot to bundle payments using an episode-based model. The approach is less about the cost of drugs—and more about the overall cost of treatment.

Related Content


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts